Skip to main content

Epigenomics, Predictive Biosciences Extend Agreement on Prostate Cancer Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Predictive Biosciences today said that Predictive Biosciences will develop a prostate cancer test using the GSTP1 biomarker, under a licensing agreement extension.

The agreement, originally forged in 2009, gave Predictive the option to develop the test using the biomarker. In announcing today that it is executing that option, Predictive added that it will also commercialize the test. In return, Epigenomics will receive a one-time fee.

The German cancer diagnostic company also is eligible for royalties from future sales of the test, which is still under development.

Additional details of the deal were not disclosed.

In a statement, the companies said that methylation of the GSTP1 gene is a well-established biomarker for prostate cancer, and a test that can detect methylated GSTP1 DNA in urine or tissue, combined with conventional histopathology, could lead to more accurate diagnoses.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.